We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
175 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMGEVITA adalimumab (rch) 80mg/0.8mL injection solution syringe within a pen injector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMGEVITA adalimumab (rch) 40mg/0.4mL injection solution syringe within a pen injector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMGEVITA adalimumab (rch) 40mg/0.4mL injection solution syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AMGEVITA adalimumab (rch) 20mg/0.2mL injection solution syringe.
-
Australian public assessment report (AusPar)Tepezza has been approved for the treatment of moderate to severe Thyroid Eye Disease.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IMDELLTRA tarlatamab 10 mg powder for injection vial with intravenous (IV) solution stabiliser vial composite pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IMDELLTRA tarlatamab 1 mg powder for injection vial with intravenous (IV) solution stabiliser vial composite pack.
-
Australian public assessment report (AusPar)UPLIZNA (inebilizumab) is for the treatment of adult patients with neuromyelitis optica spectrum disorders who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TEPEZZA teprotumumab 500 mg injection powder vial.